NCT07080216 Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
| NCT ID | NCT07080216 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Condition | Cervical Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-09-23 |
| Primary Completion | 2027-08 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Eligibility Criteria
Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form. * Female 18-75 years of age; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Exclusion Criteria: * Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.